← back to search

Daniel Ford

The University of Sydney · AU
Area of research
Nephrology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Dialysis and Renal Disease Management, Renal and Vascular Pathologies, Chronic Kidney Disease and Diabetes, and Acute Kidney Injury Research.
h-index
17
citations
921
works
107
NIH funding
—
primary concept
—
email
✉ Find email ↗

Recent publications

Antiviral cyclic peptides targeting the main protease of SARS-CoV-2
Chemical Science 2022cited by 62position: middledoi
Discovery of Potent Cyclic Sulfopeptide Chemokine Inhibitors via Reprogrammed Genetic Code mRNA Display
Journal of the American Chemical Society 2020cited by 30position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Toby Passioura · The University of Sydney2 papers (2020–2022)Richard J. Payne · The University of Sydney2 papers (2020–2022)Jason Johansen‐Leete · The University of Sydney2 papers (2020–2022)Gottfried Otting · Australian National University1 papers (2022–2022)Ram Prasad Bhusal · Monash University1 papers (2020–2020)Mithun C. Mahawaththa · Australian National University1 papers (2022–2022)Martin J. Stone · Monash University1 papers (2020–2020)Kasuni B. Ekanayake · Australian National University1 papers (2022–2022)Anthony J. O’Donoghue · University of California San Diego1 papers (2022–2022)Rebecca L. Frkic · Australian National University1 papers (2022–2022)Colin J. Jackson · Australian National University1 papers (2022–2022)Stephanie Luedtke · University of California San Diego1 papers (2022–2022)Stuart Turville · UNSW Sydney1 papers (2022–2022)Minglong Liu · Utrecht University1 papers (2020–2020)Anupriya Aggarwal · Data611 papers (2022–2022)Max J. Bedding · The University of Sydney1 papers (2022–2022)Simon R. Foster · Texas Children's Hospital1 papers (2020–2020)Christoph Nitsche · Australian National University1 papers (2022–2022)Sven Ullrich · Australian National University1 papers (2022–2022)Mark Larance · The University of Sydney1 papers (2022–2022)